Published in Drugs on November 01, 2014
Management of Venous Thromboembolism: Recent Advances in Oral Anticoagulation Therapy. Ann Pharmacother (2016) 0.75
Critical appraisal of dabigatran in the treatment of deep vein thrombosis and pulmonary embolism. J Blood Med (2015) 0.75
Possible failure of novel direct-acting oral anticoagulants in management of pulmonary embolism: a case report. J Med Case Rep (2016) 0.75
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med (2012) 11.86
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med (2003) 11.00
Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med (2012) 10.64
Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med (2010) 9.92
Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med (2009) 9.17
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med (2013) 7.76
Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med (2013) 7.00
The epidemiology of venous thromboembolism. Circulation (2003) 6.97
Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med (2013) 6.71
Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med (2012) 6.42
Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost (2005) 5.92
Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol (2013) 5.56
Apixaban for extended treatment of venous thromboembolism. N Engl J Med (2012) 4.37
Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation (2013) 3.73
Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med (2007) 3.64
Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med (1986) 3.00
Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study. Arch Intern Med (1999) 2.98
Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N Engl J Med (1979) 2.91
Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med (1990) 2.63
Massive pulmonary embolism. Circulation (2006) 2.27
The Worcester Venous Thromboembolism study: a population-based study of the clinical epidemiology of venous thromboembolism. J Gen Intern Med (2006) 2.21
Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J (2013) 2.21
The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica (2007) 2.00
Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations. J Manag Care Pharm (2007) 1.89
Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. JAMA (2005) 1.87
Novel oral anticoagulants in patients with renal insufficiency: a meta-analysis of randomized trials. Can J Cardiol (2014) 1.59
Venous thromboembolism: risk factors for recurrence. Arterioscler Thromb Vasc Biol (2009) 1.46
Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review. Arch Intern Med (2010) 1.27
Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis. N Engl J Med (1992) 1.27
Incidence of and mortality from venous thromboembolism in a real-world population: the Q-VTE Study Cohort. Am J Med (2013) 1.22
Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study--methodological implications for clinical trials. J Thromb Haemost (2013) 1.05
Resolution of thromboemboli in patients with acute pulmonary embolism: a systematic review. Chest (2006) 1.05
Recurrent venous thromboembolism. Am Fam Physician (2011) 1.03
Diagnostic management of clinically suspected acute deep vein thrombosis. Br J Haematol (2009) 0.95
Hospital costs of acute pulmonary embolism. Am J Med (2013) 0.95
The diagnostic value of compression ultrasonography in patients with suspected recurrent deep vein thrombosis. Thromb Haemost (2002) 0.93
Is the campaign to prevent VTE in hospitalized patients working? Chest (2010) 0.83
Emergency Physician Performed Ultrasound for DVT Evaluation. Thrombosis (2011) 0.81
Danger ahead: watch out for indirect comparisons! J Am Coll Cardiol (2012) 0.80
Diagnosis and anticoagulant treatment. Clin Appl Thromb Hemost (2013) 0.77
New Oral Anticoagulants in Patients With Cancer: Current State of Evidence. Am J Ther (2015) 0.77
The effect of excessive anticoagulation on mortality and morbidity in hospitalized patients with anticoagulant-related major hemorrhage. Arch Intern Med (2004) 2.11
International normalized ratio increase before warfarin-associated hemorrhage: brief and subtle. Arch Intern Med (2004) 1.55
Thrombosis in suspected heparin-induced thrombocytopenia occurs more often with high antibody levels. Am J Med (2011) 1.48
Predictors of major hemorrhage following fibrinolysis for acute pulmonary embolism. Am J Cardiol (2005) 1.34
Clinical characteristics, management, and outcomes of patients diagnosed with acute pulmonary embolism in the emergency department: initial report of EMPEROR (Multicenter Emergency Medicine Pulmonary Embolism in the Real World Registry). J Am Coll Cardiol (2011) 1.19
How many hospital pharmacy medication dispensing errors go undetected? Jt Comm J Qual Patient Saf (2006) 1.06
Pattern of infliximab utilization in rheumatoid arthritis patients at an academic medical center. Arthritis Rheum (2005) 1.06
Time trends in warfarin-associated hemorrhage. Am J Cardiol (2004) 1.02
Venous thromboembolic disease. J Natl Compr Canc Netw (2013) 1.01
Electronic alerts for hospitalized high-VTE risk patients not receiving prophylaxis: a cohort study. J Thromb Thrombolysis (2007) 0.99
Venous thromboembolic disease. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2006) 0.98
Anticoagulation-associated adverse drug events. Am J Med (2011) 0.96
Evaluation of dexmedetomidine versus propofol-based sedation therapy in mechanically ventilated cardiac surgery patients at a tertiary academic medical center. Crit Pathw Cardiol (2010) 0.95
Technology utilization to prevent medication errors. Curr Drug Saf (2010) 0.95
Anticoagulants: A Review of the Pharmacology, Dosing, and Complications. Curr Emerg Hosp Med Rep (2013) 0.95
Patient education program for venous thromboembolism prevention in hospitalized patients. Am J Med (2012) 0.94
Venous thromboembolic disease. J Natl Compr Canc Netw (2011) 0.93
Rivaroxaban: practical considerations for ensuring safety and efficacy. Pharmacotherapy (2013) 0.90
Venous thromboembolic disease. NCCN. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2008) 0.87
Dabigatran etexilate in clinical practice: confronting challenges to improve safety and effectiveness. Pharmacotherapy (2011) 0.85
Cardiology patient pages. Prevention of deep vein thrombosis and pulmonary embolism. Circulation (2004) 0.84
The nonpharmacist business manager: key qualifications and skills for success. Am J Health Syst Pharm (2011) 0.83
New antithrombotics: the impact on global health care. Thromb Res (2011) 0.79
Medication errors in a pharmacy-based bar-code-repackaging center. Am J Health Syst Pharm (2006) 0.79
Venous thromboembolic events in hospitalised medical patients. Thromb Haemost (2009) 0.78
Venous thromboembolism in hospitalized patients with active cancer. Clin Appl Thromb Hemost (2013) 0.77
Cost analysis of "bridging therapy" with low-molecular-weight heparin versus unfractionated heparin during temporary interruption of chronic anticoagulation. Am J Cardiol (2004) 0.77
Prescription of fondaparinux in hospitalised patients. Thromb Haemost (2009) 0.77
Efficacy and safety of novel anticoagulants compared with established agents. Ther Adv Hematol (2011) 0.77
Hospital budget implications of substituting dabigatran for warfarin in an anticoagulation service. Clin Appl Thromb Hemost (2011) 0.76
A Comparison of Drug Shortages in the Hospital Setting in the United States and Saudi Arabia: An Exploratory Analysis. Hosp Pharm (2016) 0.75
Effect of dabigatran on referrals to and switching from warfarin in two academic anticoagulation management services. Am J Cardiol (2013) 0.75
Comment: venous thromboembolism prophylaxis conversion in nonsurgical inpatients. Ann Pharmacother (2003) 0.75
Consultant's Playbook: A Survey of Pharmacy Consultant Experiences Among Hospitals In the University HealthSystem Consortium. P T (2013) 0.75
Review of Nonformulary Medication Approvals in an Academic Medical Center. Jt Comm J Qual Patient Saf (2016) 0.75
Heparin-induced thrombocytopenia (HIT): clinical and economic outcomes. Thromb Haemost (2008) 0.75
Impact of an immunoglobulin G-specific enzyme-linked immunosorbent assay on the management of heparin-induced thrombocytopenia. Pharmacotherapy (2013) 0.75
Aligning pharmacy and health-system objectives to eliminate central-line-associated bacteremias. Am J Health Syst Pharm (2009) 0.75
Bridging Experience With Eptifibatide After Stent Implantation. Crit Pathw Cardiol (2016) 0.75
Rivaroxaban to prevent pulmonary embolism after hip or knee replacement. Circulation (2012) 0.75